Omeros Corp (OMER):企業の財務・戦略的SWOT分析

◆英語タイトル:Omeros Corp (OMER) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3055
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Omeros Corp (OMER) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s pipeline products include Omidria, a phenylephrine and ketorolac injection and its product candidates are intended for the treatment of ophthalmological, arthroscopic, urological and other surgical procedures including thrombotic microangiopathies, complement-mediated glomerulopathies, addictive and compulsive disorders, and others. Its preclinical product candidates are intended for treatment of bleeding disorders, alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Omeros Corp Key Recent Developments

Aug 09,2018: Omeros reports second quarter 2018 financial results
May 10,2018: Omeros Reports First Quarter 2018 Financial Results
Apr 11,2018: Omeros Announces Amendment of Credit Facility
Mar 01,2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results
Nov 09,2017: Omeros Reports Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Omeros Corp – Key Facts 5
Omeros Corp – Key Employees 6
Omeros Corp – Key Employee Biographies 7
Omeros Corp – Major Products and Services 9
Omeros Corp – History 10
Omeros Corp – Company Statement 11
Omeros Corp – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Omeros Corp – Business Description 14
R&D Overview 14
Omeros Corp – SWOT Analysis 15
SWOT Analysis – Overview 15
Omeros Corp – Strengths 15
Omeros Corp – Weaknesses 16
Omeros Corp – Opportunities 17
Omeros Corp – Threats 18
Omeros Corp – Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios – Capital Market Ratios 20
Financial Ratios – Annual Ratios 21
Performance Chart 23
Financial Performance 23
Financial Ratios – Interim Ratios 24
Financial Ratios – Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Omeros Corp, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Aug 09, 2018: Omeros reports second quarter 2018 financial results 29
May 10, 2018: Omeros Reports First Quarter 2018 Financial Results 32
Apr 11, 2018: Omeros Announces Amendment of Credit Facility 34
Mar 01, 2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results 35
Nov 09, 2017: Omeros Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Omeros Reports Second Quarter 2017 Financial Results 39
Jun 29, 2017: Omeros Releases Statement in Response to Recent False Report 41
May 10, 2017: Omeros Reports First Quarter 2017 Financial Results 42
Mar 16, 2017: Omeros Reports Fourth Quarter and Year-End 2016 Financial Results 44
Section 6 – Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Omeros Corp, Key Facts 5
Omeros Corp, Key Employees 6
Omeros Corp, Key Employee Biographies 7
Omeros Corp, Major Products and Services 9
Omeros Corp, History 10
Omeros Corp, Subsidiaries 12
Omeros Corp, Key Competitors 19
Omeros Corp, Ratios based on current share price 20
Omeros Corp, Annual Ratios 21
Omeros Corp, Annual Ratios (Cont...1) 22
Omeros Corp, Interim Ratios 24
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Omeros Corp, Recent Deals Summary 28
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49

List of Figures
Omeros Corp, Performance Chart (2013 - 2017) 23
Omeros Corp, Ratio Charts 25
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27

★海外企業調査レポート[Omeros Corp (OMER):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ACTIVE Network, LLC:企業のM&A・事業提携・投資動向
    ACTIVE Network, LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ACTIVE Network, LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Advicenne SA (ADVIC)-製薬・医療分野:企業M&A・提携分析
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company’s product portfolio includes ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It offer …
  • Mithra Pharmaceuticals SA (MITRA):企業の財務・戦略的SWOT分析
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • 3-V Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 3-V Biosciences Inc (3-V Biosciences) is a clinical-stage pharmaceutical company that develops novel therapeutics in metabolic diseases. The company offers TVB-2640, a fatty acid synthase inhibitor used for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast c …
  • Hoegh LNG Holdings Ltd (HLNG):企業の財務・戦略的SWOT分析
    Summary Hoegh LNG Holdings Ltd (Hoegh LNG), formerly known as Leif Hoegh & Co Ltd is an oil and gas company that offers floating energy solutions. The company's services include floating storage and regasification unit solutions, in-house ship management, floating LNG energy services, LNG regasifica …
  • TV Asahi Corporation (9409):企業の財務・戦略的SWOT分析
    TV Asahi Corporation (9409) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC), a subsidiary of Hebrew University of Jerusalem, is a technology transfer company. The company offers marketing and licensing the inventions, products, and technologies developed by the university's faculty, …
  • AVJennings Limited:企業の戦略・SWOT・財務情報
    AVJennings Limited - Strategy, SWOT and Corporate Finance Report Summary AVJennings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GR. Sarantis S.A.:企業の戦略・SWOT・財務分析
    GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report Summary GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PAR Technology Corp (PAR):企業の財務・戦略的SWOT分析
    Summary PAR Technology Corp (PAR) is a technology company that offers systems and solutions for the hospitality industry. The company offers services such as project management, education services, deployment services, on-site field services, depot repair, and managed services. It also implements fo …
  • HSE Integrated Ltd:企業の戦略的SWOT分析
    HSE Integrated Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • TIBCO Software, Inc.:企業の戦略・SWOT・財務情報
    TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Debiotech SA:医療機器:M&Aディール及び事業提携情報
    Summary Debiotech SA (Debiotech) is a medical device company that develops therapeutic devices and diagnostic products. The company’s products include patch-pump, injection, multi-fluidic cassette type system, infusion pump and microsystems. It develops products in the areas of implantable and exter …
  • Canadian Zeolite Corp.:企業の戦略・SWOT・財務情報
    Canadian Zeolite Corp. - Strategy, SWOT and Corporate Finance Report Summary Canadian Zeolite Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Amscan Holdings, Inc.:企業の戦略・SWOT・財務情報
    Amscan Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amscan Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bellicum Pharmaceuticals Inc (BLCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, which is engaged in developing cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the …
  • XTL Biopharmaceuticals Ltd (XTLB):企業の財務・戦略的SWOT分析
    Summary XTL Biopharmaceuticals Ltd (XTL) is a drug development company that focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company’s pipeline products include hCDR1 peptide and recombinant human erythropoietin …
  • Noble Energy, Inc.:戦略・SWOT・企業財務分析
    Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Honshu Chemical Industry Co Ltd (4115):企業の財務・戦略的SWOT分析
    Honshu Chemical Industry Co Ltd (4115) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Corium International Inc (CORI):製薬・医療:M&Aディール及び事業提携情報
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆